Showing results (151-160 of 516) with videos related to

Sort By:
Pageof 52
Circulation Research|April 13, 2012
Endothelial cell palmitoylproteomic identifies novel lipid-modified targets and potential substrates for protein acyl transferasesEthan P Marin, Behrad Derakhshan, TuKiet T Lam, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1989
Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenaseB Escalante, W C Sessa, J R Falck, et al.
Journal of Cardiovascular Pharmacology|September 1, 1990
Cytochrome P450-dependent arachidonic acid metabolites, 19- and 20-hydroxyeicosatetraenoic acids, enhance sodium-potassium ATPase activity in vascular smooth muscleB Escalante, W C Sessa, J R Falck, et al.
Investigational New Drugs|January 1, 1984
Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral dosesS Kaplan, C Sessa, Y Willems, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 25, 1996
Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signalingG García-Cardeña, P Oh, J Liu, et al.
Blood|December 25, 2010
Endothelial reticulon-4B (Nogo-B) regulates ICAM-1-mediated leukocyte transmigration and acute inflammationAnnarita Di Lorenzo, Thomas D Manes, Alberto Davalos, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 10, 2010
MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and functionSebastian Albinsson, Yajaira Suarez, Athanasia Skoura, et al.
Investigational New Drugs|January 1, 1984
A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-scheduleR A Joss, S Kaplan, A Goldhirsch, et al.
British Journal of Clinical Pharmacology|December 23, 1998
Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscleF Stanke, P Devillier, D Bréant, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trialC Sessa, G Bolis, N Colombo, et al.
Pageof 52